TET2 and neoplasm: One antigen presentation process was identified in cluster 9 in the TET2-KO tumor treated with VC among those top 20 enriched pathways (Figure 3D), consistent with previous data showing that loss of TET2 expression in the tumor does not block the effect of VC on the dendritic cell/macrophage cluster.